Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Sponsor
Hebei Medical University
Study ID
NCT02510469
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mesylate Tablets 500 mg qd p.o.

Study Details

The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.

Key Dates

Start date
Jul 31, 2015
Status verified
Oct 2017
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Maintenance Therapy After Adjuvant Chemotherapy
    Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
  • No Intervention: Only Adjuvant Chemotherapy
    No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)

Primary Outcome Measure

Disease free survival [ Time Frame: An expected average of 2 years ]

Central Contacts

Related Studies